Fmr LLC Has $1.19 Billion Holdings in bluebird bio Inc (BLUE)

Fmr LLC raised its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 8.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,123,687 shares of the biotechnology company’s stock after purchasing an additional 605,797 shares during the quarter. Fmr LLC owned 0.15% of bluebird bio worth $1,186,058,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. BlackRock Inc. boosted its position in bluebird bio by 7.9% during the 3rd quarter. BlackRock Inc. now owns 2,952,089 shares of the biotechnology company’s stock valued at $431,005,000 after buying an additional 216,914 shares during the period. OppenheimerFunds Inc. boosted its position in bluebird bio by 3.0% during the 2nd quarter. OppenheimerFunds Inc. now owns 794,126 shares of the biotechnology company’s stock valued at $124,638,000 after buying an additional 23,016 shares during the period. First Trust Advisors LP boosted its position in bluebird bio by 63.2% during the 3rd quarter. First Trust Advisors LP now owns 601,883 shares of the biotechnology company’s stock valued at $87,875,000 after buying an additional 233,175 shares during the period. Bank of New York Mellon Corp boosted its position in bluebird bio by 86.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 581,695 shares of the biotechnology company’s stock valued at $84,926,000 after buying an additional 269,074 shares during the period. Finally, Jennison Associates LLC boosted its position in bluebird bio by 0.8% during the 3rd quarter. Jennison Associates LLC now owns 516,984 shares of the biotechnology company’s stock valued at $75,480,000 after buying an additional 4,244 shares during the period. 99.66% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently commented on the stock. William Blair reaffirmed a “buy” rating on shares of bluebird bio in a research report on Wednesday, September 5th. Cantor Fitzgerald set a $122.00 target price on shares of bluebird bio and gave the stock a “sell” rating in a research report on Wednesday, September 5th. Maxim Group dropped their target price on shares of bluebird bio to $163.00 and set a “hold” rating for the company in a research report on Monday, July 30th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of bluebird bio in a research report on Thursday, August 2nd. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $208.00 target price on shares of bluebird bio in a research report on Friday, August 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $206.79.

Shares of bluebird bio stock opened at $122.14 on Friday. bluebird bio Inc has a 1 year low of $102.21 and a 1 year high of $236.17.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.90) by $0.17. The company had revenue of $11.50 million during the quarter, compared to analyst estimates of $6.90 million. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. bluebird bio’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same period last year, the business earned ($1.73) EPS. As a group, sell-side analysts expect that bluebird bio Inc will post -10.54 EPS for the current fiscal year.

In other bluebird bio news, insider Jeffrey T. Walsh sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $175.40, for a total transaction of $3,508,000.00. Following the completion of the sale, the insider now directly owns 44,238 shares in the company, valued at approximately $7,759,345.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Davidson sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $166.64, for a total transaction of $1,166,480.00. Following the sale, the insider now owns 31,905 shares of the company’s stock, valued at $5,316,649.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,600 shares of company stock valued at $7,118,427. 3.00% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This news story was posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/11/24/fmr-llc-has-1-19-billion-holdings-in-bluebird-bio-inc-blue.html.

bluebird bio Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Recommended Story: What is intrinsic value?

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply